What are the recommended diagnostic methods and treatment regimens for histoplasmosis, including dosing for mild to moderate acute pulmonary disease in immunocompetent adults, severe disease, immunocompromised patients, and pregnant patients?

Histoplasmosis: Diagnosis and Treatment

Diagnostic Approach

Obtain tissue for histopathological examination using fungal stains (Grocott methenamine silver or periodic acid-Schiff) whenever possible, as this provides the most definitive diagnosis. 1

Key Diagnostic Methods

• Histopathology: Submit all biopsied tissues for fungal staining; sensitivity varies with disease burden and immune status 1
• Culture: Growth of Histoplasma capsulatum in culture is diagnostic; most labs use DNA probe for identification 1
  • Blood cultures have ~50% sensitivity in advanced HIV (improved with lysis-centrifugation method) 1
  • Cultures should be incubated at 25-30°C for 4-8 weeks 1
• Antigen detection: Histoplasma antigen in urine or serum enables rapid diagnosis and is useful for longitudinal monitoring 1, 2
• Serology: Most useful for chronic pulmonary histoplasmosis; less reliable in severe immunosuppression 1
• Imaging: Chest, abdominal, and CNS imaging according to clinical presentation 1

---

Treatment Recommendations by Disease Severity

Mild-to-Moderate Acute Pulmonary Histoplasmosis (Immunocompetent Adults)

Treatment is usually unnecessary for mild disease. 1

• If symptoms persist >1 month: Itraconazole 200 mg three times daily for 3 days, then 200 mg once or twice daily for 6-12 weeks 1
• Itraconazole capsules require high gastric acidity (take with food or cola); use solution formulation in patients on antacids, H2 blockers, or proton pump inhibitors 1
• Monitor itraconazole blood levels after ≥2 weeks to ensure adequate drug exposure 1

Moderately Severe to Severe Acute Pulmonary Histoplasmosis

Liposomal amphotericin B (3.0 mg/kg daily IV) for 1-2 weeks is the preferred initial therapy, followed by itraconazole step-down. 1

Induction Phase:

• Preferred: Liposomal amphotericin B 3.0 mg/kg daily IV for 1-2 weeks 1
• Alternative: Other lipid formulation at 5.0 mg/kg daily (may be preferred for cost or tolerability) 1
• Alternative: Amphotericin B deoxycholate 0.7-1.0 mg/kg daily IV in patients at low risk for nephrotoxicity 1
• Add methylprednisolone 0.5-1.0 mg/kg daily IV during first 1-2 weeks if respiratory complications develop (hypoxemia or significant respiratory distress) 1

Consolidation Phase:

• Itraconazole 200 mg three times daily for 3 days, then 200 mg twice daily for total duration of ≥12 months 1

Chronic Cavitary Pulmonary Histoplasmosis

Itraconazole 200 mg three times daily for 3 days, then once or twice daily for at least 1 year is recommended. 1

• Some experts prefer 18-24 months duration due to relapse risk 1
• Monitor itraconazole blood levels after ≥2 weeks of therapy 1

Progressive Disseminated Histoplasmosis

Liposomal amphotericin B provides superior survival compared to amphotericin B deoxycholate in patients with AIDS and disseminated disease. 1

Severe Disease:

• Liposomal amphotericin B 3.0 mg/kg daily for 1-2 weeks 1
• Randomized trial showed higher response rate (88% vs 64%) and lower mortality (2% vs 13%) compared to amphotericin B deoxycholate 1
• Follow with itraconazole 200 mg twice daily for ≥12 months 1

Mild-to-Moderate Disseminated Disease:

• Itraconazole 200 mg three times daily for 3 days, then 200 mg twice daily for ≥12 months 1
• Response rate: 100% for disseminated disease in early studies 1
• Fluconazole is less effective (70% response rate) and associated with resistance development 1

Immunocompromised Patients

Lifelong suppressive therapy with itraconazole 200 mg daily may be required if immunosuppression cannot be reversed. 1

• Also indicated for patients who relapse despite appropriate therapy 1
• In HIV patients: Continue itraconazole maintenance for ≥1 year, then discontinue if CD4 count ≥150 cells/µL 3
• Antiretroviral therapy should be initiated immediately with antifungal treatment (low risk of immune reconstitution syndrome) 3
• For tumor necrosis factor-α inhibitor-associated histoplasmosis: Discontinue immunosuppression during antifungal therapy; may reinstitute after ~12 months if clinical response achieved and antigen testing negative 1

Pregnant Patients

The guidelines do not provide specific recommendations for pregnant patients, though a 2025 update addressing this population is referenced 4. In the absence of specific guidance, treatment decisions must weigh maternal mortality risk against fetal safety, with amphotericin B formulations generally considered safer than azoles during pregnancy.

---

Monitoring During Therapy

• Itraconazole levels: Obtain after ≥2 weeks of therapy to ensure adequate exposure 1
• Antigen levels: Measure during therapy and for 12 months after completion 1
• Hepatic enzymes: Monitor before and during azole therapy due to hepatotoxicity risk 1

---

Conditions NOT Requiring Antifungal Treatment

Antifungal therapy is not recommended for asymptomatic pulmonary nodules (histoplasmomas), broncholithiasis, mediastinal fibrosis, or presumed ocular histoplasmosis syndrome. 1

• Histoplasmomas: No evidence that antifungals affect nodules or that they contain viable organisms 1
• Broncholithiasis: Requires bronchoscopic or surgical removal of broncholith 1
• Mediastinal fibrosis: Neither antifungal nor anti-inflammatory treatment ameliorates outcome in most cases 1

---

Key Clinical Pitfalls

• Itraconazole absorption: Capsules require gastric acidity; use solution formulation (on empty stomach) in patients on acid-suppressing medications 1
• Drug level monitoring: Failure to check itraconazole levels is common; levels are essential to ensure therapeutic exposure 1
• Fluconazole resistance: Avoid fluconazole as primary therapy; it is less effective than itraconazole and resistance can develop 1
• Echinocandins: No evidence supports their use in histoplasmosis 1
• Voriconazole: Not routinely recommended 1